JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 21, 2003; DOI: 10.1124/jpet.102.047092


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.102.047092v1
305/1/131    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, Q.
Right arrow Articles by Roth, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, Q.
Right arrow Articles by Roth, B. L.

Vol. 305, Issue 1, 131-142, April 2003

L-Homocysteine Sulfinic Acid and Other Acidic Homocysteine Derivatives Are Potent and Selective Metabotropic Glutamate Receptor Agonists

Qi Shi , Jason E. Savage, Sandra J. Hufeisen, Laura Rauser, Ewa Grajkowska, Paul Ernsberger, Jarda T. Wroblewski, Joseph H. Nadeau and Bryan L. Roth1

Departments of Biochemistry (Q.S., B.L.R.), Genetics (Q.S., J.H.N.), and Nutrition (P.E.), National Institute of Mental Health Psychoactive Drug Screening Program (J.E.S., S.J.H., L.R., B.L.R.), School of Medicine, Case Western Reserve University, Cleveland, Ohio; and Department of Pharmacology (J.T.W., E.G), Georgetown University Medical Center, Washington, D.C.

Moderate hyperhomocysteinemia is associated with several diseases, including coronary artery disease, stroke, Alzheimer's disease, schizophrenia, and spina bifida. However, the mechanisms for their pathogenesis are unknown but could involve the interaction of homocysteine or its metabolites with molecular targets such as neurotransmitter receptors, channels, or transporters. We discovered that L-homocysteine sulfinic acid (L-HCSA), L-homocysteic acid, L-cysteine sulfinic acid, and L-cysteic acid are potent and effective agonists at several rat metabotropic glutamate receptors (mGluRs). These acidic homocysteine derivatives 1) stimulated phosphoinositide hydrolysis in the cells stably expressing the mGluR1, mGluR5, or mGluR8 (plus Galpha qi9) and 2) inhibited the forskolin-induced cAMP accumulation in the cells stably expressing mGluR2, mGluR4, or mGluR6, with different potencies and efficacies depending on receptor subtypes. Of the four compounds, L-HCSA is the most potent agonist at mGluR1, mGluR2, mGluR4, mGluR5, mGluR6, and mGluR8. The effects of the four agonists were selective for mGluRs because activity was not discovered when L-HCSA and several other homocysteine derivatives were screened against a large panel of cloned neurotransmitter receptors, channels, and transporters. These findings imply that mGluRs are candidate G-protein-coupled receptors for mediating the intracellular signaling events induced by acidic homocysteine derivatives. The relevance of these findings for the role of mGluRs in the pathogenesis of homocysteine-mediated phenomena is discussed.


1 This work was supported in part by the National Institute of Mental Health Psychoactive Drug Screening Program Grant MHN80002, Award KO2 MH01366 to B.L.R., Grant HL58982 to J.H.N., and Grant NS37436 to J.T.W.


0022-3565/03/3051-0131$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
J. B. Othersen, J. C. Maize Jr., R. F. Woolson, and M. N. Budisavljevic
Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure
Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3179 - 3185.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
K. S. Moshal, U. Sen, N. Tyagi, B. Henderson, M. Steed, A. V. Ovechkin, and S. C. Tyagi
Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway
Am J Physiol Cell Physiol, March 1, 2006; 290(3): C883 - C891.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Chavkin, S. Sud, W. Jin, J. Stewart, J. K. Zjawiony, D. J. Siebert, B. A. Toth, S. J. Hufeisen, and B. L. Roth
Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious {kappa}-Opioid Receptor Agonist: Structural and Functional Considerations
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1197 - 1203.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. B. Rothman, N. Vu, J. S. Partilla, B. L. Roth, S. J. Hufeisen, B. A. Compton-Toth, J. Birkes, R. Young, and R. A. Glennon
In Vitro Characterization of Ephedrine-Related Stereoisomers at Biogenic Amine Transporters and the Receptorome Reveals Selective Actions as Norepinephrine Transporter Substrates
J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 138 - 145.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.